Goldman Sachs Raises CPHD Target From $30 To $32

April 14, 2011 7:40 AM | 8 seconds read | Make a Comment

Goldman Sachs is raising its PT on shares of Cepheid

CPHD

from $30 to $32. Cepheid closed Wednesday at $28.75.

Posted In: Price Target Analyst Ratings Biotechnology cepheid Goldman Sachs Health Care

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.